Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C symptoms and diagnosis news

Show

From To
Global progress towards hepatitis C elimination still blocked by cost of treatment, lack of diagnosis

Nine countries – Australia, Brazil, Egypt, Georgia, Germany, Iceland, Japan, the Netherlands and Qatar – are on course to eliminate hepatitis C by 2030, according to

Published
01 November 2017
By
Keith Alcorn
UK elimination of hepatitis C in jeopardy unless more patients found

Just one in three people with hepatitis C in the United Kingdom has been diagnosed according to the latest estimates released at this year’s World

Published
01 November 2017
By
Keith Alcorn
Hepatitis C testing linked to reduced opioid use among people who inject drugs

Getting tested for hepatitis C virus (HCV) was associated with reduced drug use, especially among those who tested positive, but even people who tested negative saw some

Published
25 October 2017
By
Liz Highleyman
Screening for Hepatitis C Improves Opioid Abuse Treatment Outcomes

Research presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – shows people in treatment for opioid substance abuse significantly lowered their non‐prescribed opioid use after testing positive for hepatitis C virus.

Published
23 October 2017
From
AASLD
Rapid fibrosis progression in large proportion of HIV-positive gay men after acute HCV

Over a third of HIV-positive gay men develop significant liver fibrosis after an episode of acute hepatitis C virus (HCV) infection, German investigators report in

Published
11 October 2017
By
Michael Carter
Hep C: An end in sight?

Despite its prevalence, hepatitis C has long been under-prioritised by health services. But could new drugs and a new commitment from the NHS mean we may finally see this killer condition eradicated?

Published
05 October 2017
From
Drink & Drug News
US FDA approves nivolumab immunotherapy for liver cancer

The US Food and Drug Administration (FDA) last week granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumour activity, for people

Published
28 September 2017
By
Liz Highleyman
Liver fibrosis speeds up around the menopause in women with HIV and HCV co-infection

Menopause is associated with accelerated liver fibrosis in women with HIV and hepatitis C virus (HCV) co-infection, investigators from the United States report in the online edition of

Published
22 August 2017
By
Michael Carter
Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV

Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in

Published
17 August 2017
By
Michael Carter
Targeting MSM with HIV: Treatment as Prevention in the Netherlands

As part of Dutch HIV guidelines, all individuals with HIV are screened for hepatitis C. Anne Boerekamps, MD, of Erasmus University Medical Center in Rotterdam, the Netherlands, spoke with HCV Next about the Dutch approach, the relevant data, and other topics associated with screening and treating MSM.

Published
18 July 2017
From
Healio Hepatology
← First12345...18Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.